Kedrion awarded national tender for Portuguese plasma manufacturing
Mar 02, 2023 |
CORPORATE
First shipments of plasma from Porto and Lisbon were received in the beginning of February
Kedrion strengthens its network of plasma collection centers
Dec 05, 2022 |
CORPORATE
Five centers acquired in the Czech Republic
Permira Funds and the Marcucci family complete investment in Kedrion & BPL
Sep 01, 2022 |
CORPORATE
Announced appointment of Ugo Di Francesco as CEO
Kedrion Biopharma Recognized for innovation in Treating Rare Disease
Jun 28, 2022 |
CORPORATE
Prestigious recognition presented for the first ever treatment for Plasminogen Deficiency
World Hemophilia Day: Kedrion’s commitment
Apr 13, 2022 |
CORPORATE
Guaranteeing equitable access to treatment is the central theme of the 2022 edition
Kedrion-Pharmacosmos partnership for the treatment of Anemia in Italy
Mar 03, 2022 |
CORPORATE
Exclusive agreement signed for the distribution of a novel iron-based therapy
Val Romberg completes his assignement as Kedrion’s CEO
Jan 31, 2022 |
CORPORATE
Kedrion and LFB sign industrial cooperation agreement
Jan 31, 2022 |
CORPORATE
Scope is supplying Immunoglobulins to meet patient demand in France
Kedrion grows in North America as it completes acquisition of Prometic
Oct 18, 2021 |
CORPORATE
Launch is planned for the first ever FDA-approved treatment for patients suffering from Congenital Plasminogen Deficiency